Observational epidemiology within randomized clinical trials: Getting a lot for (almost) nothing

Progress in Cardiovascular Diseases

Volumn 54, Issue 4, 2012, Pages 367-371

  Howard, George ^a   Howard, Virginia J ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENALAPRIL; IRBESARTAN; PLACEBO;

ARTICLE; CLINICAL OBSERVATION; COHORT ANALYSIS; DATA ANALYSIS; DIABETIC NEPHROPATHY; EPIDEMIOLOGY; HEART FAILURE; HUMAN; MEDICAL INFORMATION; MEDICAL RESEARCH; RANDOMIZED CONTROLLED TRIAL (TOPIC);

COHORT STUDIES; EPIDEMIOLOGIC STUDIES; HUMANS; LONGITUDINAL STUDIES; OBSERVATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STATISTICS AS TOPIC;

EID: 84855411937     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2011.08.003     Document Type: Article

References (22)

1. Martinson B.C., Crain A.L., Sherwood N.E., et al. Population reach and recruitment bias in a maintenance RCT in physically active older adults. J Phys Act Health 2010, 7:127-135.
2. Surman C.B., Monuteaux M.C., Petty C.R., et al. Representativeness of participants in a clinical trial for attention-deficit/hyperactivity disorder? Comparison with adults from a large observational study. J Clin Psychiatry 2010, 71:1612-1616.
3. Herrington D.M., Fong J., Sempos C.T., et al. Comparison of the Heart and Estrogen/Progestin Replacement Study (HERS) cohort with women with coronary disease from the National Health and Nutrition Examination Survey III (NHANES III). Am Heart J 1998, 136:115-124.
4. Ahmad N., Boutron I., Dechartres A., et al. Geographical representativeness of published and ongoing randomized controlled trials. The example of: tobacco consumption and HIV infection. PLoS One 2011, 6:e16878.
5. Olschewski M., Scheurlen H. Comprehensive cohort study: an alternative to randomized consent design in a breast preservation trial. Methods Inf in Med 1985, 24:131-134.
6. Schmoor C., Olschewski M., Schumacher M. Randomized and non-randomized patients in clinical trials: experiences with comprehensive cohort studies. Stat Med 1996, 15:263-271.
7. Ford J.G., Howerton M.W., Lai G.Y., et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 2008, 112:228-242.
8. Williams B., Irvine L., Mcinnis A.R., et al. When "no" might not quite mean "no"; the importance of informed and meaningful non-consent: results from a survey of individuals refusing participation in a health-related research project. BMC Health Serv Res 2007, 7:59.
9. Wren T.A., Otsuka N.Y., Bowen R.E., et al. Influence of gait analysis on decision-making for lower extremity orthopaedic surgery: Baseline data from a randomized controlled trial. Gait Posture 2011, 34:364-369.
10. Rogers Z.R., Wang W.C., Luo Z., et al. Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. Blood 2011, 117:2614-2617.
11. McKelvie R.S., Komajda M., McMurray J., et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. J Card Fail 2010, 16:128-134.
12. Riddle M.C., Ambrosius W.T., Brillon D.J., et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD. Diabetes Care 2010, 33:983-990.
13. Desai R.V., Banach M., Ahmed M.I., et al. Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial). Am J Cardiol 2010, 106:221-227.
14. Kim C., Edelstein S.L., Crandall J.P., et al. Menopause and risk of diabetes in the Diabetes Prevention Program. Menopause 2011, 18:857-868. for the Diabetes Prevention Program Research Group.
15. Ovbiagele B., Campbell S., Faiz A., et al. Relationship between non-specific prescription pill adherence and ischemic stroke outcomes. Cerebrovasc Dis 2010, 29:146-153.
16. Smith M.R., Cook R., Lee K.A., et al. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 2011, 117:2077-2085.
17. Titan S.M., Zatz R., Graciolli F.G., et al. FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol 2011, 6:241-247.
18. Irizarry M.C., Webb D.J., Bains C., et al. Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease. J Alzheimers Dis 2008, 14:301-311.
19. Liu C., Blumhardt L.D. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts. J Neurol Neurosurg Psychiatry 2000, 6:450-457.
20. Hobson R.W., Howard V.J., Roubin G.S., et al. Howard G for the CREST Investigators. Carotid artery stenting is associated with increased complications in octogenarians: 30-day stroke and death rates in the CREST lead-in phase. J Vasc Surg 2004, 40:1106-1111.
21. Belin R.J., Greenland P., Allison M., et al. Diet quality and the risk of cardiovascular disease: the Women's Health Initiative (WHI). Am J Clin Nutr 2011, 94:49-57.
22. Thomas A.J., Eberly L.E., Davey Smith G., et al. Race/ethnicity, income, major risk factors, and cardiovascular disease mortality. Am J Public Health 2005, 95:1417-1423.